Oral Micronized Progesterone Compounding Legal Status

FDA Approval History of Oral Micronized Progesterone

Prometrium received FDA approval on May 14, 1998, making it the first commercially available oral micronized progesterone product in the United States. Before 1998, clinicians who wanted bioidentical progesterone for hormone therapy had no approved oral option; compounding was the only route. FDA approval changed the legal calculus entirely.

The Original NDA and What It Covered

Solvay Pharmaceuticals submitted New Drug Application (NDA) 019781 for Prometrium. The agency approved two capsule strengths, 100 mg and 200 mg, indicated for use in postmenopausal women receiving conjugated equine estrogens (CEE) to prevent endometrial hyperplasia, and for the treatment of secondary amenorrhea in premenopausal women [1]. The approval was based on endometrial biopsy data showing that 200 mg/day for 12 days per cycle adequately protected the endometrium against CEE-induced hyperplasia.

Generic Approvals

FDA has since approved multiple Abbreviated New Drug Applications (ANDAs) for generic oral micronized progesterone 100 mg and 200 mg capsules. Approved generics include products from Teva Pharmaceuticals, Perrigo, and Virtus Pharmaceuticals, all of which must demonstrate bioequivalence to Prometrium under 21 CFR Part 320. Prescribers and pharmacists can verify current approval status through Drugs@FDA at accessdata.fda.gov [2].

The availability of multiple FDA-approved generics is legally significant. FDA's compounding guidance consistently cites the existence of an approved commercial product as a primary factor limiting the permissibility of compounded copies.

What the FDA-Approved Label Actually Says

Understanding the package insert is the starting point for any compounding analysis. The Prometrium prescribing information covers indications, dosing, contraindications, warnings, and pharmacokinetics in detail [1].

Approved Doses and Administration

The label specifies 200 mg orally once daily at bedtime for 12 consecutive days per 28-day cycle in women receiving CEE. For secondary amenorrhea, the dose is 400 mg at bedtime for 10 days. Both regimens instruct administration with food to maximize absorption, because taking the capsule on an empty stomach reduces peak plasma concentration substantially.

The 12-days-per-cycle regimen matters for compounding discussions. Some patients and prescribers request continuous daily progesterone at lower doses (50 mg or 100 mg), a use not explicitly listed in the approved labeling. That off-label dosing pattern is one reason physicians sometimes seek compounded formulations.

Contraindications and Key Warnings

The Prometrium label carries several absolute contraindications [1]:

• Undiagnosed abnormal uterine bleeding
• Known or suspected breast cancer or history of breast cancer
• Known or suspected estrogen- or progestogen-dependent neoplasia
• Active deep vein thrombosis, pulmonary embolism, or history of these conditions
• Active arterial thromboembolic disease (stroke, MI)
• Known liver dysfunction or disease
• Peanut allergy (the capsule contains peanut oil as the vehicle)

The peanut oil contraindication is clinically underappreciated. A patient with a documented peanut allergy has a legitimate medical need for an alternative formulation, and this is one of the clearest clinical justifications for a compounded progesterone preparation.

The WHI Signal and Label Updates

The Women's Health Initiative (WHI) randomized trial, which used medroxyprogesterone acetate (MPA) rather than micronized progesterone, generated the boxed warning language about breast cancer and cardiovascular risk that appears on all progestogen-containing hormone therapy products. The FDA applied similar language broadly across the class. Prescribers should note that the WHI data apply specifically to CEE plus MPA, not to oral micronized progesterone, a distinction the Endocrine Society and the Menopause Society have both addressed in guideline statements.

Compounding Legal Status: The Federal Framework

This is the area where confusion is most common. The short answer: compounding oral micronized progesterone is legal but restricted. The longer answer requires understanding two different federal pathways.

503A: Traditional Compounding Pharmacies

Under Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act), a licensed pharmacist may compound a drug for an identified individual patient based on a valid prescription from a licensed practitioner, provided several conditions are met [3]:

1. The compound must not be a copy of a commercially available drug product without a documented clinical difference.
2. The compound must not appear on FDA's list of drug products that have been withdrawn or removed from the market for safety reasons.
3. The bulk drug substance used must be on FDA's 503A bulks list or meet other stated criteria.
4. The compound must not be on the FDA Demonstrably Difficult to Compound (DDC) list.

Progesterone as a bulk active pharmaceutical ingredient (API) currently appears on FDA's list of bulk substances that may be used in 503A compounding under Category 1, meaning there is sufficient clinical evidence supporting its use in compounded preparations [4]. However, the existence of Prometrium and its generics means a 503A pharmacy cannot simply compound a standard 100 mg or 200 mg progesterone capsule and dispense it as though no approved alternative existed. The pharmacist or prescriber must document why the compounded version is clinically necessary for that specific patient.

Accepted 503A justifications include peanut allergy (the most common), a documented intolerance to inactive ingredients in approved products, or a need for a dose or dosage form not available commercially (such as a topical or sublingual preparation).

503B: Outsourcing Facilities

Section 503B of the FD&C Act created a separate category of outsourcing facilities that may produce larger batches of compounded drugs without patient-specific prescriptions, subject to Current Good Manufacturing Practice (CGMP) requirements and FDA registration [3]. These facilities may supply compounded progesterone to healthcare settings, but they face an additional constraint: FDA has authority to place drugs on a 503B "difficult to compound" or "not appropriate for outsourcing" list.

As of the date of this review, oral micronized progesterone in standard capsule form has not been placed on the FDA's 503B DDC list, meaning outsourcing facilities may produce it. Still, 503B facilities cannot produce copies of commercially available drugs in a way that undermines the drug approval system. Formulations that differ meaningfully from approved products (e.g., different strengths, modified-release capsules, sublingual troche forms) occupy a legally more defensible position.

State Pharmacy Board Overlay

Federal law sets the floor, not the ceiling. State pharmacy boards impose additional requirements. California, New York, and Florida, for example, each have their own compounding pharmacy regulations that may be stricter than federal minimums on labeling, beyond-use dating, and dispensing records. Any telehealth platform dispensing compounded oral progesterone must verify compliance in the patient's state of residence.

The Clinical Evidence That Shapes Prescribing Decisions

Understanding why clinicians sometimes prefer oral micronized progesterone over synthetic progestogens requires a look at the trial data.

The PEPI Trial: Lipid Profile Advantages

The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial, published in JAMA in 1995 (N=875), randomized postmenopausal women to five hormone regimens and followed them for three years. CEE plus micronized progesterone 200 mg/day produced a statistically significant improvement in HDL cholesterol compared to CEE plus MPA (P<0.001 for the comparison of HDL change). Women receiving micronized progesterone had HDL levels that were nearly as favorable as women receiving estrogen alone, while MPA largely blunted the estrogen-associated HDL benefit [5]. This finding established a clinical rationale for preferring micronized progesterone over MPA in cardiovascular-risk-conscious patients.

E3N Cohort: Breast Cancer Risk Differentiation

The French E3N prospective cohort (N=54,548 women) found that the combination of oral estrogen with synthetic progestogens was associated with significantly higher breast cancer risk than estrogen combined with micronized progesterone (relative risk approximately 1.00 for estrogen plus micronized progesterone vs. 1.69 for estrogen plus synthetic progestogen) [6]. This observational data does not prove causality, but it has influenced European prescribing practices substantially and is cited in North American clinical practice guidelines.

Pharmacokinetics and the Food Effect

Oral micronized progesterone is subject to extensive first-pass hepatic metabolism. Absolute bioavailability is approximately 10% under fasting conditions. Taking Prometrium with food increases C-max roughly 3-fold and AUC roughly 2.3-fold. This food effect is clinically meaningful: patients who take their dose in the morning on an empty stomach may not achieve adequate endometrial protection, a prescribing error that leads some clinicians to request higher-dose compounded preparations without first correcting administration timing.

Sedation and CNS Effects

Oral micronized progesterone is converted to allopregnanolone, a neurosteroid that acts as a positive allosteric modulator of GABA-A receptors. This produces measurable sedation at bedtime doses, which is why the approved label specifies bedtime administration. For some patients this is a benefit, aiding sleep. For others, particularly those who need daytime dosing for cycle regulation, sedation is a limiting side effect and represents another legitimate clinical reason to explore alternative formulations or delivery routes.

Compounded Oral Progesterone vs. Prometrium: What Is Actually Different

Compounded and commercial oral micronized progesterone share the same active molecule, but several formulation differences can carry clinical weight.

Particle Size and Micronization

Bioavailability of progesterone depends heavily on particle size. "Micronized" refers to particles ground to approximately 10 microns. Generic manufacturers must demonstrate bioequivalence to Prometrium; compounding pharmacies are not held to the same standard. A compounding pharmacy may use a bulk API that is nominally micronized but may differ from the particle-size specification Solvay used in the original NDA. This can translate to unpredictable serum levels.

Vehicle and Excipients

Prometrium uses peanut oil as the fill vehicle. Some compounding pharmacies use olive oil, sunflower oil, or other plant-based oils, which may alter progesterone solubility and absorption. Patients switching from Prometrium to a compounded product should have serum progesterone levels monitored if endometrial protection is the primary goal.

Custom Strengths

Compounding allows strengths not available commercially. The most commonly requested non-standard strengths are 50 mg (for low-dose continuous regimens) and 300 mg (for patients who metabolize the drug rapidly). FDA-approved products cover only 100 mg and 200 mg.

Safety Profile: What Post-Market Data Show

Prometrium has been in clinical use for more than 25 years, generating a substantial post-market safety record.

FDA Adverse Event Reporting and Sentinel

FDA's MedWatch database and the Sentinel System (a distributed active surveillance program with access to data from more than 100 million patients) have not generated new class-wide safety signals for oral micronized progesterone beyond those already reflected in the approved labeling [7]. The dominant safety concern remains the class-level cardiovascular and breast cancer warnings derived from WHI data.

Venous Thromboembolism

Unlike synthetic progestogens such as norethindrone acetate, oral micronized progesterone has not been independently associated with increased venous thromboembolism (VTE) risk in observational studies. The Menopause Society's 2022 position statement notes that the VTE risk of oral combined hormone therapy is driven primarily by the estrogen component and is lower with transdermal estrogen delivery regardless of progestogen type [8].

Drug Interactions

Progesterone is metabolized primarily by CYP3A4. Drugs that induce CYP3A4 (rifampin, carbamazepine, phenytoin) may reduce progesterone exposure meaningfully. CYP3A4 inhibitors (ketoconazole, ritonavir) may increase exposure. These interactions are listed in the Prometrium prescribing information and apply equally to compounded oral progesterone.

Practical Prescribing Guidance for Telehealth Platforms

Telehealth prescribers dispensing or directing patients to compounded oral progesterone must satisfy several documentation requirements.

Documenting Medical Necessity

A bare prescription for "compounded progesterone 100 mg capsule" without a stated clinical reason may expose the pharmacy to FDA enforcement action and the prescriber to state board scrutiny. The prescription or accompanying clinical note should specify the reason, for example: "Peanut allergy prevents use of Prometrium. Compounded progesterone 100 mg capsule in olive oil vehicle ordered per 503A." A documented allergy in the electronic health record strengthens the justification.

Monitoring Recommendations

Patients on compounded oral progesterone for endometrial protection should have an endometrial biopsy or transvaginal ultrasound per standard menopausal management guidelines if breakthrough bleeding occurs. Serum progesterone levels are not routinely used to monitor endometrial protection efficacy, but levels drawn 2 to 4 hours post-dose with food can verify absorption in patients with suspected malabsorption.

When to Default to the Approved Product

The approved product should be the default in the absence of a specific contraindication or documented intolerance. As the Menopause Society states in its 2022 Hormone Therapy Position Statement: "FDA-approved hormone therapy products should be used when available; compounded preparations should be reserved for individualized patient needs that cannot be met by approved products" [8].